Plain-English translation of NCT06441110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Urinary Bladder Neoplasms research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether tislelizumab, a type of immunotherapy medication, works better when combined with BCG (a standard bladder cancer treatment delivered directly into the bladder) to prevent bladder cancer from returning after surgery. The study involves 76 patients at multiple hospitals and aims to understand both how well this combination works and whether it is safe for people with intermediate or high-risk, non-muscle-invasive bladder cancer.
While BCG has been used to treat bladder cancer for many years, doctors want to know if adding this new immunotherapy medication can improve results and reduce the chance of the cancer coming back. Most evidence so far has been from smaller or retrospective studies, so this larger, prospective trial will provide stronger proof of whether this combination is truly beneficial.
You likely qualify if…
You likely don't qualify if…
You will receive instillations (liquid medication placed directly into your bladder through a catheter) combining the new immunotherapy medication with BCG over a period of time. The study will involve multiple visits to the hospital for these treatments and follow-up appointments to monitor how well the treatment is working and to check for any side effects. You will have regular blood tests, imaging scans, and other examinations to track your health and whether your cancer returns.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China